Based on the ICON PLC stock forecast from 7 analysts, the average analyst target price for ICON PLC is USD 325.50 over the next 12 months. ICON PLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ICON PLC is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, ICON PLC’s stock price was USD 213.26. ICON PLC’s stock price has changed by +4.92% over the past week, -0.46% over the past month and -24.00% over the last year.
No recent analyst target price found for ICON PLC
No recent average analyst rating found for ICON PLC
Company Overview ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland. Read Less
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of prog...Read More
Frequently Asked Questions About ICON PLC (ICLR) Stock
Based on ratings from 7 analysts ICON PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 15 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ICLR's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for ICLR is USD 325.50 over the next 12 months. The maximum analyst target price is USD 383 while the minimum anlayst target price is USD 225.
ICLR stock's Price/Earning ratio is 24.22.
Our analysis grades ICLR stock's Price / Earning ratio at F. This means that ICLR stock's Price/Earning ratio is above 50% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this ICLR may be fairly valued for its sector
The last closing price of ICLR's stock was USD 213.26.
The most recent market capitalization for ICLR is USD 17.95B.
Based on targets from 7 analysts, the average taret price for ICLR is projected at USD 325.50 over the next 12 months.
This means that ICLR's stock price may go up by +52.63% over the next 12 months.
We can't find any ETFs which contains ICON PLC's stock.
As per our most recent records ICON PLC has 42,250 Employees.
ICON PLC's registered address is South County Business Park, Dublin, Ireland, D18 X5R3.
You can get more information about it from ICON PLC's website at https://www.iconplc.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ICON PLC (ICLR) Stock
Based on ratings from 7 analysts ICON PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 15 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ICLR's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for ICLR is USD 325.50 over the next 12 months. The maximum analyst target price is USD 383 while the minimum anlayst target price is USD 225.
ICLR stock's Price/Earning ratio is 24.22.
Our analysis grades ICLR stock's Price / Earning ratio at F. This means that ICLR stock's Price/Earning ratio is above 50% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this ICLR may be fairly valued for its sector
The last closing price of ICLR's stock was USD 213.26.
The most recent market capitalization for ICLR is USD 17.95B.
Based on targets from 7 analysts, the average taret price for ICLR is projected at USD 325.50 over the next 12 months.
This means that ICLR's stock price may go up by +52.63% over the next 12 months.
We can't find any ETFs which contains ICON PLC's stock.
As per our most recent records ICON PLC has 42,250 Employees.
ICON PLC's registered address is South County Business Park, Dublin, Ireland, D18 X5R3.
You can get more information about it from ICON PLC's website at https://www.iconplc.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ICLR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
